CR20220280A - Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 - Google Patents

Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2

Info

Publication number
CR20220280A
CR20220280A CR20220280A CR20220280A CR20220280A CR 20220280 A CR20220280 A CR 20220280A CR 20220280 A CR20220280 A CR 20220280A CR 20220280 A CR20220280 A CR 20220280A CR 20220280 A CR20220280 A CR 20220280A
Authority
CR
Costa Rica
Prior art keywords
inhibitor
alk2
combination therapy
jak2
compounds
Prior art date
Application number
CR20220280A
Other languages
English (en)
Inventor
Michelle Pusey
Matthew C Stubbs
Ying-Nan Pan Chen
Yaoyu Chen
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CR20220280A publication Critical patent/CR20220280A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan compuestos, composiciones farmacéuticas que comprenden dichos compuestosy métodos para usar dichos compustos para tratar enfermedades o transtornos asociados con JAK/2 y/o ALK2.
CR20220280A 2019-11-22 2020-11-20 Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 CR20220280A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962939241P 2019-11-22 2019-11-22
US202062980562P 2020-02-24 2020-02-24
US202063035194P 2020-06-05 2020-06-05
US202063056768P 2020-07-27 2020-07-27
PCT/US2020/061497 WO2021102258A1 (en) 2019-11-22 2020-11-20 Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor

Publications (1)

Publication Number Publication Date
CR20220280A true CR20220280A (es) 2022-09-02

Family

ID=73699492

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220280A CR20220280A (es) 2019-11-22 2020-11-20 Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2

Country Status (17)

Country Link
US (2) US11738026B2 (es)
EP (1) EP4061367A1 (es)
JP (1) JP7717065B2 (es)
KR (1) KR20220107213A (es)
CN (1) CN115038443A (es)
AU (1) AU2020388638A1 (es)
BR (1) BR112022009710A2 (es)
CA (1) CA3160312A1 (es)
CL (1) CL2022001325A1 (es)
CR (1) CR20220280A (es)
EC (1) ECSP22044525A (es)
IL (1) IL293085A (es)
MX (1) MX2022006176A (es)
PE (1) PE20230251A1 (es)
PH (1) PH12022551052A1 (es)
TW (1) TW202131926A (es)
WO (1) WO2021102258A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7504880B2 (ja) 2018-10-26 2024-06-24 ケロス セラピューティクス インコーポレイテッド Ａｌｋ２阻害剤の結晶形
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
JP2023530316A (ja) * 2020-06-16 2023-07-14 インサイト・コーポレイション 貧血の治療のためのａｌｋ２阻害剤
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2023081212A1 (en) * 2021-11-02 2023-05-11 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
CN116478145B (zh) * 2022-04-13 2024-02-02 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3832460A (en) 1971-03-19 1974-08-27 C Kosti Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
US6638905B2 (en) 1993-06-18 2003-10-28 The Salk Institute For Biological Studies Cloning and recombinant production of CFR receptor(s)
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6624138B1 (en) 2001-09-27 2003-09-23 Gp Medical Drug-loaded biological material chemically treated with genipin
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
ATE232382T1 (de) 1998-09-10 2003-02-15 Nycomed Danmark As Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen
EP1382339B1 (en) * 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
OA12514A (en) 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
EP1142566B1 (fr) 2000-04-07 2003-10-01 Laboratoire Medidom S.A. Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate
IL152771A0 (en) 2000-06-26 2003-06-24 Pfizer Prod Inc PYRROLO(2,3-d) PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
EP1414443B1 (en) 2001-08-01 2006-11-15 Merck & Co., Inc. BENZIMIDAZO 4,5-f|ISOQUINOLINONE DERIVATIVES
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
US7444183B2 (en) 2003-02-03 2008-10-28 Enteromedics, Inc. Intraluminal electrode apparatus and method
JP2006518381A (ja) 2003-02-07 2006-08-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール
EP1623216A2 (en) 2003-04-11 2006-02-08 SGX Pharmaceuticals, Inc. Compound libraries and methods for drug discovery
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
WO2005067546A2 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
CA2567935C (en) 2004-05-27 2009-10-27 Pfizer Limited Aminopyridine derivatives as selective dopamine d3 agonists
US7138423B2 (en) 2004-07-20 2006-11-21 Bristol-Myers Squibb Company Arylpyrrolidine derivatives as NK-1 /SSRI antagonists
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
CA2596830A1 (en) 2005-02-03 2006-09-14 Vertex Pharmaceuticals Incorporated Pyrrolopyrimidines useful as inhibitors of protein kinase
AU2006234627C1 (en) 2005-04-08 2009-11-26 Eisai R & D Management Co., Ltd. Therapeutic agent for dyskinesia
WO2006127587A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US20130137681A1 (en) 2005-12-13 2013-05-30 Incyte Corporation HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
AR059036A1 (es) 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CA2658362A1 (en) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
BRPI0718029A2 (pt) 2006-11-06 2013-11-26 Supergen Inc Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
WO2009064835A1 (en) 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
MX2010013876A (es) 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
CA3121743A1 (en) 2009-01-15 2010-07-22 Incyte Holdings Corporation Processes for preparing jak inhibitors and related intermediate compounds
JP5775070B2 (ja) 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
SG176111A1 (en) 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
KR101921850B1 (ko) 2009-10-09 2018-11-23 인사이트 홀딩스 코포레이션 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
EP2536729A1 (en) 2010-02-18 2012-12-26 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
RS54824B1 (sr) 2010-05-21 2016-10-31 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
DK2646443T3 (en) 2010-12-01 2014-11-17 Pfizer CAT-II inhibitors
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
CA2827673C (en) 2011-02-18 2020-10-27 Novartis Pharma Ag Mtor/jak inhibitor combination therapy
WO2012161877A1 (en) 2011-05-23 2012-11-29 Merck Patent Gmbh Pyridine-and pyrazine derivatives
ES2595407T3 (es) * 2011-06-14 2016-12-29 Novartis Ag Combinación de panobinostat y ruxolitinib en el tratamiento de cáncer, tal como una neoplasia mieloproliferativa
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EP2753605B1 (en) 2011-09-09 2019-03-27 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
AU2013274030B2 (en) 2012-06-15 2016-07-07 Sun Pharmaceutical Industries, Inc. Deuterated derivatives of ruxolitinib
KR102092988B1 (ko) 2012-09-28 2020-03-25 벤더르빌트 유니버시티 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들
CN113384546A (zh) * 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
WO2014138088A1 (en) 2013-03-04 2014-09-12 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
MX394360B (es) * 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
CN105555313A (zh) 2013-08-20 2016-05-04 因赛特公司 在c-反应蛋白水平较高的实体肿瘤患者中的存活益处
BR112016008632A8 (pt) 2013-10-21 2020-03-17 Merck Patent Gmbh compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
BR112017015273A2 (pt) 2015-01-20 2018-01-09 Merial Inc. compostos e composições antihelmínticos e método de utilizações dos mesmos
US10710980B2 (en) 2016-07-20 2020-07-14 Novartis Ag Aminopyridine derivatives and their use as selective ALK-2 inhibitors
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
KR20210047308A (ko) 2018-08-21 2021-04-29 시에라 온코로지, 인코퍼레이티드 골수섬유증을 치료하는 혈소판 수-불특정 방법
US20220372136A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating anemia of chronic disease
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
JP2023530316A (ja) 2020-06-16 2023-07-14 インサイト・コーポレイション 貧血の治療のためのａｌｋ２阻害剤

Also Published As

Publication number Publication date
MX2022006176A (es) 2022-08-17
ECSP22044525A (es) 2022-08-31
IL293085A (en) 2022-07-01
PH12022551052A1 (en) 2023-05-29
WO2021102258A1 (en) 2021-05-27
PE20230251A1 (es) 2023-02-07
BR112022009710A2 (pt) 2022-08-09
CL2022001325A1 (es) 2023-03-24
US11738026B2 (en) 2023-08-29
KR20220107213A (ko) 2022-08-02
US20210154195A1 (en) 2021-05-27
US20240041887A1 (en) 2024-02-08
AU2020388638A1 (en) 2022-06-30
CN115038443A (zh) 2022-09-09
JP2023502742A (ja) 2023-01-25
TW202131926A (zh) 2021-09-01
CA3160312A1 (en) 2021-05-27
EP4061367A1 (en) 2022-09-28
JP7717065B2 (ja) 2025-08-01

Similar Documents

Publication Publication Date Title
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
ZA202310316B (en) Fluoroalkyl-oxadiazoles and uses thereof
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
MX2022016422A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
BR112022008294A2 (pt) Composições de profármaco e métodos de tratamento
MX2021013317A (es) Terapias de combinacion que comprenden inhibidores de apremilast y tyk2.
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
MX2024007938A (es) Indoles, indazoles y analogos relacionados para inhibir yap/taz-tead.
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
MX2022002443A (es) Compuestos inhibidores de perk.
CO2022001354A2 (es) Métodos para tratar o prevenir la atrofia muscular espinal
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
JOP20250311A1 (ar) مثبطات tyk2 وتركيبات وطرق لها
AR116024A1 (es) Métodos de tratamiento de enfermedades neurodegenerativas
CL2022001167A1 (es) Tratamiento de trastornos hepáticos
CL2023002120A1 (es) Terapia combinada de un inhibidor de alk2 y un inhibidor de jak2
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MY204443A (en) Pyridopyrimidinone derivatives for use as axl inhibitors